{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:54:09Z","timestamp":1740174849960,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["surg case rep"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cardiovascular surgery for patients with a history of heparin-induced thrombocytopenia (HIT) with thrombosis requires careful perioperative anticoagulation therapy. When cardiovascular surgery is required for patients having \u2018remote\u2019 HIT, such as those who had a history of HIT and platelet factor-4\/heparin antibodies turned out to be negative, it is recommended that re-exposure to heparin should be limited only to the intraoperative phase. However, few case reports have described detailed strategies for perioperative anticoagulation regimens.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We present the case of a 76-year-old woman, presenting with unstable angina pectoris and requiring coronary artery bypass grafting. She had a history of cardiac resuscitation and percutaneous coronary intervention for unstable angina pectoris with ventricular tachycardia 7\u00a0years prior, which caused HIT with thrombosis resulting in amputation of four fingers. On admission, platelet factor-4\/heparin antibodies, biomarkers for HIT were not detected; the platelet count was 18.0\u2009\u00d7\u200910<jats:sup>4<\/jats:sup>\/\u00b5l. Off-pump coronary artery bypass grafting was performed using heparin; argatroban infusion was continued until 9\u00a0h prior to the operation and restarted 3\u00a0h postoperatively, bridged with regular warfarin from 4\u00a0days to 3\u00a0months postoperatively. Platelet factor-4 \/heparin antibodies were detected on postoperative day 8 without any clinical symptoms and became negative by day 91.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We consider this anticoagulation strategy is effective especially in countries, where bivalirudin is not available. Re-exposure to heparin in cardiovascular surgery for patients with a history of \u2018remote HIT\u2019 is reasonable, and appropriate anticoagulation is important for an uneventful postoperative course.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40792-021-01339-9","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T10:03:12Z","timestamp":1639994592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Off-pump coronary artery bypass with heparin in a patient with a history of heparin-induced thrombocytopenia: a case report"],"prefix":"10.1186","volume":"7","author":[{"given":"Yuya","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6731-2007","authenticated-orcid":false,"given":"Aya","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Motomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"1339_CR1","doi-asserted-by":"publisher","first-page":"e495S","DOI":"10.1378\/chest.11-2303","volume":"141","author":"LA Linkins","year":"2012","unstructured":"Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e495S \u2013 e530.","journal-title":"Chest"},{"key":"1339_CR2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1182\/blood-2016-01-635003","volume":"128","author":"TE Warkentin","year":"2016","unstructured":"Warkentin TE, Anderson JA. How I treat patients with a history of heparin-induced thrombocytopenia. Blood. 2016;128:348\u201359.","journal-title":"Blood"},{"key":"1339_CR3","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJM200104263441704","volume":"344","author":"TE Warkentin","year":"2001","unstructured":"Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286\u201392.","journal-title":"N Engl J Med"},{"key":"1339_CR4","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S0002-9343(96)00258-6","volume":"101","author":"TE Warkentin","year":"1996","unstructured":"Warkentin TE, Kelton JG. A 14-year study of heparin- induced thrombocytopenia. Am J Med. 1996;101:502\u20137.","journal-title":"Am J Med"},{"key":"1339_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0002-9343(99)00124-2","volume":"106","author":"DE Wallis","year":"1999","unstructured":"Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med. 1999;106:629\u201335.","journal-title":"Am J Med"},{"key":"1339_CR6","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","volume":"2","author":"A Cuker","year":"2018","unstructured":"Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2:3360\u201392.","journal-title":"Blood Adv"},{"key":"1339_CR7","unstructured":"Pharmaceuticals and Medical Devices Agency. Japanese Pharmacopoeia 18th Edition. 2021. https:\/\/www.pmda.go.jp\/english\/rs-sb-std\/standards-development\/jp\/0029.html."},{"key":"1339_CR8","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/S0003-4975(99)00827-9","volume":"68","author":"ND Nader","year":"1999","unstructured":"Nader ND, Khadra WZ, Reich NT, Bacon DR, Salerno TA, Panos AL. Blood product use in cardiac revascularization: comparison of on- and off-pump techniques. Ann Thorac Surg. 1999;68:1640\u20133.","journal-title":"Ann Thorac Surg"},{"key":"1339_CR9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jtcvs.2005.09.057","volume":"131","author":"CM Dyke","year":"2006","unstructured":"Dyke CM, Smedira NG, Koster A, Aronson S, McCarthy HL 2nd, Kirshner R, et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg. 2006;131:533\u20139.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1339_CR10","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1056\/NEJM200008173430718","volume":"343","author":"B P\u00f6tzsch","year":"2000","unstructured":"P\u00f6tzsch B, Kl\u00f6vekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med. 2000;343:515.","journal-title":"N Engl J Med"},{"key":"1339_CR11","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1177\/1076029615578167","volume":"21","author":"P Dhakal","year":"2015","unstructured":"Dhakal P, Giri S, Pathak R, Bhatt VR. Heparin reexposure in patients with a history of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost. 2015;21:626\u201331.","journal-title":"Clin Appl Thromb Hemost"},{"key":"1339_CR12","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1213\/00000539-200302000-00009","volume":"96","author":"GA Nuttall","year":"2003","unstructured":"Nuttall GA, Oliver WC Jr, Santrach PJ, McBane RD, Erpelding DB, Marver CL, et al. Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series. Anesth Analg. 2003;96:344\u201350.","journal-title":"Anesth Analg"},{"key":"1339_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2165\/00002018-200932030-00003","volume":"32","author":"MJ Hursting","year":"2009","unstructured":"Hursting MJ, Soffer J. Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia. Drug Saf. 2009;32:203\u201318.","journal-title":"Drug Saf"},{"key":"1339_CR14","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.athoracsur.2006.09.038","volume":"83","author":"A Koster","year":"2007","unstructured":"Koster A, Dyke CM, Aldea G, Smedira NG, McCarthy HL 2nd, Aronson S, et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg. 2007;83:572\u20137.","journal-title":"Ann Thorac Surg"},{"key":"1339_CR15","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jccase.2013.02.013","volume":"8","author":"K Matsuyama","year":"2013","unstructured":"Matsuyama K, Kuinose M, Maruno K, Takahashi S, Toguchi K, Iwahashi T, et al. Difficulty in the management of anticoagulation with argatroban during off-pump coronary artery bypass grafting. J Cardiol Cases. 2013;8:e1\u20132.","journal-title":"J Cardiol Cases"},{"key":"1339_CR16","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1510\/icvts.2009.215848","volume":"10","author":"F Follis","year":"2010","unstructured":"Follis F, Filippone G, Montalbano G, Floriano M, Lobianco E, D\u2019Ancona G, et al. Argatroban as a substitute of heparin during cardiopulmonary bypass: a safe alternative? Interact Cardiovasc Thorac Surg. 2010;10:592\u20136.","journal-title":"Interact Cardiovasc Thorac Surg"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40792-021-01339-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40792-021-01339-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40792-021-01339-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T10:43:24Z","timestamp":1639997004000},"score":1,"resource":{"primary":{"URL":"https:\/\/surgicalcasereports.springeropen.com\/articles\/10.1186\/s40792-021-01339-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1339"],"URL":"https:\/\/doi.org\/10.1186\/s40792-021-01339-9","relation":{},"ISSN":["2198-7793"],"issn-type":[{"type":"electronic","value":"2198-7793"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"10 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from the patient for the reporting of this case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"265"}}